Ibrahim-Achi, Z.; Jorge-Pérez, P.; Abreu-González, P.; López-Mejías, R.; Martín-González, C.; González-Gay, M.Á.; Ferraz-Amaro, I.
Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction. Antioxidants 2023, 12, 1668.
https://doi.org/10.3390/antiox12091668
AMA Style
Ibrahim-Achi Z, Jorge-Pérez P, Abreu-González P, López-Mejías R, Martín-González C, González-Gay MÁ, Ferraz-Amaro I.
Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction. Antioxidants. 2023; 12(9):1668.
https://doi.org/10.3390/antiox12091668
Chicago/Turabian Style
Ibrahim-Achi, Zeina, Pablo Jorge-Pérez, Pedro Abreu-González, Raquel López-Mejías, Candelaria Martín-González, Miguel Á. González-Gay, and Iván Ferraz-Amaro.
2023. "Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction" Antioxidants 12, no. 9: 1668.
https://doi.org/10.3390/antiox12091668
APA Style
Ibrahim-Achi, Z., Jorge-Pérez, P., Abreu-González, P., López-Mejías, R., Martín-González, C., González-Gay, M. Á., & Ferraz-Amaro, I.
(2023). Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction. Antioxidants, 12(9), 1668.
https://doi.org/10.3390/antiox12091668